Ovarian small-cell carcinoma hypercalcemic type successfully treated: a case report and literature review

Jian-jun Wang¹,*
Qi Liu²,*
Nan Wu¹
Xiao-die Zhou¹
Hai Wang¹
Xuan Wang¹
Pin Tu¹
Xiao-jun Zhou¹
Qun-li Shi¹
¹Department of Pathology, ¹Department of Obstetrics and Gynecology, Jinling Hospital, Medical School of Nanjing University, Nanjing University, Nanjing, Jiangsu, People’s Republic of China
*These authors contributed equally to this work

Abstract: Ovarian small-cell carcinoma hypercalcemic type (OSCCHT) is a relatively rare and highly fatal gynecological malignancy. Prognosis is generally poor, and no treatment guidelines are offered. Here, we report a case of OSCCHT successfully treated by complete excision and a postoperative chemotherapy scheme of carboplatin and paclitaxel. A 29-year-old female with pelvic mass and significantly increased serum calcium (4.90 mmol/L) was referred to our hospital on August 22, 2013. Abdominal ultrasonography and computed tomography revealed a pelvic nonhomogeneous echo of a 113x102 mm mass, possibly coming from the adnexa of the uterus. Preoperative examinations indicated high levels of serum calcium and relevant acute renal dysfunction; hence, continuous renal replacement therapy was performed until all tests reached minimum operation requirements. Interestingly, after excision, serum calcium levels decreased rapidly and therefore, extra calcium had to be taken in order to take the level back up to normal. The patient was diagnosed with OSCCHT based on the clinical data and pathological examinations. After six cycles of chemotherapy, the patient was in a good condition and on follow-up there were no signs of recurrence.

Keywords: small-cell carcinoma, hypercalcemic type, treatment, successful, ovary

Introduction
Primary ovarian small-cell carcinoma is a rare and aggressive gynecological malignancy with a tendency of early distant metastases and a low 5-year survival rate. There are two types of ovarian small-cell carcinomas: hypercalcemic and pulmonary. Ovarian small-cell carcinoma hypercalcemic type (OSCCHT), first described in 1975 by Scully,¹ mainly occurs in young females and is often accompanied by paraneoplastic syndrome of hypercalcemia.

OSCCHT has no specific symptoms and is often revealed as a nodular or lobulated neoplasm in one of the adnexa of the uterus. The tumor is thought to be a highly fatal neoplasm and survival prognosis is poor. The treatment of OSCCHT is challenging, and no mature therapy guidelines are offered. Here, we report a case of OSCCHT associated with severe hypercalcemia and acute renal dysfunction which was successfully treated by complete tumor excision and postoperative chemotherapy.

Case report
On August 22, 2013, a 29-year-old female presented to a local hospital with inappetence and significant weight loss (about 10 kg) over 1 month. Blood tests showed increased levels of alanine transaminase (58.9 IU/L) and alkaline phosphatase (133 IU/L) and a low serum potassium level (3.3 mmol/L). The patient was then referred to another
hospital for further examinations, and renal function tests showed an increase in urea nitrogen (9.11 mmol/L), serum creatinine (202.7 μmol/L), and uric acid (678.7 μmol/L). Abdominal ultrasonography revealed a pelvic nonhomogeneous echo of a 113×102 mm mass, and pelvic computed tomography indicated that the pelvic mass possibly came from adnexa of the uterus. No increased carcinoembryonic antigen or carbohydrate antigen (CA)-199 was noted. The patient was transferred to Jinling Hospital for further diagnosis and treatment on September 3, 2013 (day 1).

Laboratory findings on admission were as follows: serum calcium levels at 4.90 mmol/L (normal, 2.03–2.54 mmol/L), parathyroid hormone at 1.1 pmol/L (normal, 1.6–9.3 pmol/L), urea nitrogen at 13.3 mmol/L (normal, 2.86–7.14 mmol/L), serum creatinine at 219 μmol/L (normal, 44–133 μmol/L), uric acid at 678.7 μmol/L (normal, 178.4–297.4 μmol), CA125 at 43.60 U/mL (normal, <35 U/mL), and lactate dehydrogenase at 384 U/L (normal, 100–300 U/L).

During a gynecological examination a big, hard, fixed, and non-tender mass right in front of the uterus was observed. Pelvic magnetic resonance imaging revealed a less uniform mass signal with a size of 110×116×125 mm, with visible low nodular signal inside the tumor and a less clear boundary between the conjunction of the uterus and the tumor (Figure 1). No other tumor was found in the colon or bladder. Thoracic and abdominal radiography showed nothing unusual.

To study the reason behind the abnormal hypercalcemia, thyroid ultrasonography and computed tomography were performed, but no tumor was found in the thyroid or parathyroid. Thus, hypercalcemia might have been caused by the malignant tumor, and increasingly high calcium levels might have been the cause of acute renal dysfunction. Therefore, continuous renal replacement therapy was performed on day 3. An emergent operation was performed once urea nitrogen and serum creatinine tests were within normal limits after two rounds of hemodialysis on day 4.

During surgery, no adhesion between abdominal viscera was inspected. The right ovary increased approximately to the size of 12×10×10 cm with a hard, uneven, and vascular surface (Figure 2). The right fallopian tube, uterine, and left adnexa were all within the normal range. Preoperative function of blood coagulation showed a thrombin time of 26.6 seconds, fibrinogen level of 419 mg/dL, and a partially activated thromboplastin time of 58.3 seconds, which were all beyond normal limits. Examinations of frozen sections revealed a malignant tumor. Considering these facts: hypercalcemia, renal dysfunction, and abnormal dysfunction of coagulation, unilateral adnexitomy was performed. After surgery, serum calcium decreased rapidly, and on day 8 calcium levels had to be brought back up to normal levels by taking extra calcium (Figure 3). Microscopically, the tumor cells were arranged in a solid distribution, nodular, and pseudoglandular cavity patterns, with medium to large cells, eosinophilic cytoplasm, round or oval vesicular nucleus, increased karyoplasmic ratio, and pathologic mitosis (Figure 4A and B). Immunohistochemistry showed EMA (+), CK (+), C-erbB-2 (1+), CA125 (focal +), and Ki-67 proliferation index labeling ~60%, while estrogen (ER), progesterone (PR), inhibin, CD99, alpha fetoprotein (ALP), placental - type alkaline phosphatase (PLAP), CD30, and CD20 were not expressed. KRAS mutation was not detected, and no tumor cells were found in ascites cytological examination. The most striking ultrastructural features revealed no neuroendocrine granules, while visible inserted basement membrane and cell junction could be seen, suggesting tumors of an epithelial origin (Figure 4C). All in all, the final diagnosis of OSCCHT was made.

On day 9, the patient received a carboplatin and paclitaxel chemotherapy scheme when the examination of the liver and renal functions were within the normal range. On October

Figure 1 Magnetic resonance imaging of the tumor on admission.
Notes: (A) Magnetic resonance imaging (T2) displayed a less uniform mass signal with a size of 110×116×125 mm, with visible low nodular signal inside the tumor. (B) Magnetic resonance imaging (T2) showed a tumor with less clear boundary between the conjunction of the uterus and the tumor oppressing the uterus and other pelvic organs.
25, the patient received extensive excision, and postoperative pathology found para-aortic lymph node metastasis (1/13). The patient received five more rounds of chemotherapy on October 3, October 30, November 25, December 21, 2013, and January 12, 2014. The patient was in a good clinical condition, and serum calcium and urea nitrogen were found to be at normal levels during regular follow-ups (Figure 3), with no recurrence or metastasis by the latest follow-up on September 20, 2015.

**Discussion**

OSCCHT is considered as a highly aggressive variant of ovarian malignancies, associated with an extremely unfavorable prognosis. OSCCHT mainly occurs in young females (mean age: 22 years), and ~75% of patients die within 1 or 2 years. OSCCHT has no specific clinical manifestations, and is mainly presented as unilateral adnexal masses of equal incidence to the left or right side. Therefore, definitive preoperative diagnosis of OSCCHT is frequently difficult and pathological examination remains the gold standard for its diagnosis. Several reports of OSCCHT cases were found in family members, suggesting that OSCCHT could be heritable. The tumors were generally large in size, with an average diameter of 15 cm, and had a nodular or lobulated appearance with mostly solid or partially cystic sections accompanied by visible hemorrhage and necrosis. In two-thirds of cases, OSCCHT was often presented with paraneoplastic syndrome of hypercalcemia, while only 10% of cases had hypercalcemia symptoms. It is difficult to explain this phenomenon as the mechanism of hypercalcemia is not understood clearly, but it is generally believed that hypercalcemia is caused by tumor cells unlike the mechanism of neuroendocrine tumors. Related literature reported variable serum calcium levels of 2.43–4.80 mmol/L, with an average of 3.68 mmol/L. In the present case, this patient had a much higher level of serum calcium of 4.90 mmol/L preoperatively than what other literature reported, while postoperative serum calcium levels decreased to 1.9 mmol/L. Hence, on day 8, calcium levels had to be brought back up to the normal level, and it then stayed normal during the follow-ups, which indicated that increased serum calcium levels were caused by tumor cells. After surgery, serum calcium levels returned to normal, reflecting that serum calcium levels correspond with surgical treatment which might be a useful means of monitoring the disease. As serum calcium levels decreased, urea nitrogen gradually returned to normal levels, which indicated that increased serum calcium levels might induce acute renal dysfunction and, more importantly, indirectly proved that high levels of serum calcium were caused by the tumor. Some studies recommended that CA-125 could be a very useful tumor marker, which was elevated in approximately 75% of patients at diagnosis, and CA-125 levels were slightly high in the present case also.

Treatment included surgery, radiotherapy, and chemotherapy while there was no unified view on which one should be given priority, and it was so poorly differentiated that no experienced adjuvant chemotherapy guidelines were offered. OSCCHT is an ovarian epithelial cancer type in nature, and carboplatin and paclitaxel regimens are commonly used as the first-line chemotherapeutic regimen for ovarian epithelial cancers. Woopen et al reported on three cases using six cycles of carboplatin and paclitaxel as first-line therapy and reported no recurrence at the time of publishing, which is the same method and results as to what Wynn et al and the present case had. Carboplatin and paclitaxel regimens were initially used in the presented case without any progression. The situation was well stabilized and the patient’s condition improved over the following several cycles. However, a previous study reported only limited efficacy of both first line and salvage therapy in treating OSCCHT. In Harrison et al’s case report, of the

![Figure 2](image-url) Pathological characteristics.

**Notes:** The tumor displayed a nodular appearance with a diameter of ~12 cm, and cross-section showed white appearance and medium texture, with a loculus of 1.2 cm in diameter filled with a pale yellow fluid.

![Figure 3](image-url) The changing of serum calcium and urea nitrogen levels.

**Notes:** The serum calcium levels sharply decreased after complete excision (on September 6, 2013); hence, extra calcium had to be taken to increase levels back to normal. The urea nitrogen levels indicated revised renal function.
four patients who received carboplatin and paclitaxel, two had disease progression during treatment and two progressed within 3 months of chemotherapy. Another reported regimen of VPCBAE (vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, etoposide), has been used in the treatment of OSCCHT with varying success.\textsuperscript{15,16} Wallbillich et al\textsuperscript{17} presented a case series of three patients with OSCCHT with unilateral salpingo-oophorectomy followed by six cycles of chemotherapy with VPCBAE without evidence of recurrence. Walker et al\textsuperscript{18} reported that advanced stage III OSCCHT patients who received VPCBAE therapy had been disease-free for more than 10 years. Bakhru et al\textsuperscript{19} reported the case of a 14-year-old female with no evidence of disease after treatment with four cycles of VPBCAE, however, after 3 weeks there was an appearance of a large pelvic mass with metastases, and the patient was dead within 2 months. OSCCHT was initially treated like small-cell lung cancer as presented in the Gynaecological Cancer Intergroup trial,\textsuperscript{14} which established the use of cisplatin and etoposide for treating this rare subtype of ovarian cancer.\textsuperscript{4} Harrison et al\textsuperscript{14} reported that five stage I patients were alive and disease-free at a median follow-up of 50 months, noting that all long-term survivors received cisplatin and etoposide. Most of them received radiotherapy either sequentially or concurrently, while it was not possible to say that it was superior to carboplatin and paclitaxel as the patients receiving the latter combination had more advanced diseases. In another review, 27 patients received dose-intense PAVEP therapy (cisplatin, adriamycin, VePesid, cyclophosphamide), which was found to be effective and the patients had an overall 5-year survival rate of 49% and 14 stage III patients were without any sign of disease.\textsuperscript{20}

The largest series was reported by Young,\textsuperscript{1} which included 150 patients. Of these patients, 50% had stage I, 5% stage II, 43% stage III, and 1% stage IV disease. In the report, 33% of patients with stage IA were alive and disease-free at 5 years, and only 10% with stage IC and stage II, III, and IV were alive. Furthermore, patients who received adjuvant chemotherapy had better survival in International Federation of Gynecology and Obstetrics stage IA compared with those who had only surgical treatment, while there was no apparent evidence that adjuvant chemotherapy in stage IA could improve the prognosis.\textsuperscript{5} Features associated with a more favorable survival in patients with stage IA tumors included age $>30$ years, a normal preoperative serum calcium level,
tumor size <10 cm, localized stage of tumor, and the absence of large cells, while Rebecca et al. thought that tumors with a diameter >10 cm were associated with improved survival. Woopen et al. added that tumor stage appeared to play a significant role in the overall prognosis.

Stephens et al. analyzed molecular characterization of an OSCCHT patient’s sample and found some upregulation or downregulation molecular targets and suggested available potential targeted drugs. Recently, SMARCA4 mutations and SMARCA4 protein loss were identified in OSCCHT, and SMARCA4 (BRG1) loss of expression was thought to be a useful diagnostic marker of OSCCHT in ovarian tumors. Related data suggested a tumor suppressor role of SMARCA4 and that it might constitute a key therapeutic vulnerability in SMARCA4-deficient cells in the future.

**Conclusion**

OSCCHT is a rare and aggressive gynecological malignancy and has a poor prognosis. In light of this case report, we think that complete surgical management and postoperative chemotherapy are necessary. As the rarity of the tumor and lack of large series evaluating therapeutic strategies, it is obliged that more case series reports and multicenter analyses are needed to further investigate this rare disease and optimize clinical treatments.

**Acknowledgments**

The case report is part of the Ovarian Carcinoma Research Program and it has been approved by the Ethics Committee of Jinling Hospital, Medical School of Nanjing University (number 2015NZZY-013-01) and the Chinese Clinical Trial Register number was ChiCTR-OOC-15006925. This case report is only for medical communication, not for other purposes, and does not include the patient’s name and information. The patient agreed to this report being published and signed informed consent.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**
